1. Introduction

The Artificial Endocrine Doctrine is a proposed legal and regulatory framework for governing technologies that artificially influence, replace, simulate, monitor, or regulate the human endocrine system. It is particularly relevant to biotechnology law, medical-device regulation, pharmaceutical law, reproductive rights, genetic engineering, bioethics, and constitutional protection of bodily autonomy.

Important legal clarification: “Artificial Endocrine Doctrine” is not a universally recognised, independently established legal doctrine with a settled body of case law. It is better understood as an emerging analytical concept. Its legal principles must be developed by applying existing laws governing medicines, medical devices, informed consent, privacy, negligence, discrimination, and human rights.

The endocrine system consists of glands and tissues that produce hormones, including insulin, thyroid hormones, cortisol, estrogen, testosterone, and growth hormone. Artificial endocrine technologies may include:

Artificial pancreas systems and automated insulin delivery.

Hormone replacement therapies and long-acting hormone implants.

Drug-delivery devices that regulate hormone release.

Endocrine-disrupting substances and synthetic hormonal compounds.

Hormone-monitoring biosensors and predictive medical algorithms.

Experimental biological systems designed to produce or regulate hormones.

The central legal question is: Who should bear responsibility when an artificial system alters hormonal activity and causes physical, psychological, reproductive, or social harm?

The answer requires balancing patient autonomy, scientific innovation, public health, corporate responsibility, and effective regulatory supervision.

2. Meaning and scope of the doctrine

The proposed doctrine can be organised around six fundamental principles.

1. Bodily autonomy

Individuals should receive adequate information and retain meaningful control over medically significant hormonal interventions, subject to lawful exceptions.

2. Safety and efficacy

Artificial endocrine products should undergo appropriate testing, regulatory assessment, monitoring, and adverse-event reporting.

3. Proportionate accountability

Liability should reflect the conduct and responsibility of manufacturers, clinicians, hospitals, software developers, and regulators.

4. Hormonal data privacy

Sensitive endocrine measurements should be collected and used lawfully, with safeguards against unauthorised disclosure and discriminatory profiling.

5. Equality and non-discrimination

Hormonal conditions, fertility status, or use of endocrine treatment should not become unjustified grounds for exclusion from employment, education, insurance, or healthcare.

6. Continuous oversight

Safety obligations should continue after approval through surveillance, updates, recall procedures, and reassessment when new evidence emerges.

These principles are a proposed analytical framework, not six rules already recognised by courts under a single doctrine.

3. Legal framework in India

The doctrine can be analysed through existing Indian legal provisions rather than assuming that a separate endocrine statute exists.

The applicable regulatory route depends on the product's composition, intended purpose, mode of action, classification and claims. A hormone medicine, an insulin pump, a biosensor and an experimental hormone-producing cell implant do not necessarily fall under identical regulatory requirements.

4. Leading case laws and their application

There is no reported Supreme Court judgment establishing a standalone Artificial Endocrine Doctrine. The following cases provide important legal principles that could govern endocrine-related disputes.

Case 1: Samira Kohli v. Dr. Prabha Manchanda

Supreme Court of India · (2008) 2 SCC 1

Facts: A patient consented to diagnostic and operative laparoscopy. While she was under anaesthesia, the doctor performed a hysterectomy and removed her ovaries and fallopian tubes without obtaining her own consent to those additional procedures.

Judgment: The Supreme Court emphasised that valid medical consent must be voluntary, given by a competent patient, and based on adequate information. Consent to one procedure does not ordinarily authorise a substantially different procedure. The emergency exception is limited to situations in which further intervention is necessary to save life or preserve health and waiting for consent would be unreasonable.

Indian Kanoon

+1

Application to artificial endocrine law:

A patient agreeing to hormone monitoring has not automatically consented to hormone treatment.

Consent to one hormone therapy does not necessarily authorise an additional implant or irreversible intervention.

Clinicians should explain material risks, benefits, alternatives and consequences of refusing treatment.

A device's automated recommendations cannot replace legally adequate patient consent.

Legal significance: This is one of the strongest Indian authorities for the bodily-autonomy and informed-consent elements of the proposed doctrine.

Case 2: K.S. Puttaswamy v. Union of India

Supreme Court of India · (2017) 10 SCC 1

Principle: The nine-judge bench recognised privacy as a fundamental right protected by the Constitution, including dimensions of bodily privacy, decisional autonomy and informational privacy.

Application:

Suppose a wearable endocrine sensor continuously records cortisol, insulin or reproductive hormone levels and sends the data to a commercial platform. The platform then uses the information to infer fertility, stress, health risks or other personal characteristics.

Constitutional privacy principles become particularly relevant where the State collects or uses such information. Private-sector processing may also be governed by applicable data-protection statutes and other legal obligations.

A proposed endocrine governance framework would therefore require:

A lawful basis for collecting and using sensitive health-related information.

Appropriate security and limits on secondary use.

Meaningful transparency concerning automated inferences.

Safeguards against unjustified disclosure to employers, insurers or other third parties.

Legal significance: Privacy and autonomy provide a constitutional foundation for regulating artificial systems that can reveal intimate physiological information.

Case 3: Common Cause v. Union of India

Supreme Court of India · (2018) 5 SCC 1

Principle: The Supreme Court recognised the constitutional significance of dignity, autonomy and end-of-life decision-making, including the legal framework for passive euthanasia and advance medical directives, as subsequently clarified in related proceedings.

Application: Artificial endocrine technologies may sustain or regulate physiological functions in critically ill patients. Disputes can arise over continuing, withdrawing or modifying treatment when the patient has made relevant advance decisions or lacks decision-making capacity.

However, the case does not establish a general right to demand withdrawal of every endocrine treatment. The patient's circumstances, applicable medical standards and the governing legal framework remain important.

Legal significance: It supports analysis of autonomy and dignity in difficult medical decisions involving life-sustaining or physiologically significant technologies.

Case 4: Indian Medical Association v. V.P. Shantha

Supreme Court of India · (1995) 6 SCC 651

Principle: The Court addressed when medical services fall within consumer-protection law, including the treatment of paid medical services and specified exceptions.

Application: If a hospital supplies an artificial endocrine management service, the patient may have a consumer-law remedy where the applicable statutory requirements are met and the facts establish deficiency in service.

Potential disputes include:

Failure to monitor a patient using an insulin-delivery system.

Improper installation or calibration of a therapeutic device.

Inadequate follow-up after hormone therapy.

Failure to respond appropriately to reported complications.

The applicability of this decision must now be considered alongside the Consumer Protection Act, 2019 and later legal developments.

Legal significance: It helps establish a route for patient remedies without requiring a separate endocrine-specific cause of action.

Case 5: Common Cause v. Union of India

Supreme Court of India · (2018) 5 SCC 1

Principle: The Court recognised the importance of dignity, autonomy and advance medical directives in end-of-life decision-making.

Application: Consider a patient who depends on a hormone-regulating device or other artificial physiological support and later loses the ability to communicate treatment preferences. The legal questions may concern advance directives, decision-making capacity, medical judgment and the patient's previously expressed wishes.

This case offers relevant principles for such disputes, but it does not specifically regulate artificial endocrine technologies or establish an unrestricted right to discontinue any treatment.

Case 6: Indian Medical Association v. V.P. Shantha

Supreme Court of India · (1995) 6 SCC 651

Principle: The Court explained when medical treatment and hospital services fall within consumer-protection law.

Indian Kanoon

Application: A patient harmed by negligent management of an artificial endocrine system may potentially pursue a consumer complaint, depending on the nature of the service, the evidence, and the applicable statutory requirements.

For example, a hospital might fail to respond to repeated device alarms or inadequately monitor a patient receiving an automated insulin-delivery treatment. The question would be whether the service fell below the applicable standard of care, not simply whether a complication occurred.

5. Liability under the Artificial Endocrine Doctrine

The proposed doctrine requires a careful allocation of responsibility among different participants.

Liability is not automatic merely because a patient experiences a hormonal complication. A claimant generally needs to establish the relevant legal duty, breach or statutory defect, causation, and legally recognised harm. The precise requirements depend on the cause of action.

6. Important hypothetical legal disputes

The following examples illustrate how the proposed doctrine could operate.

Scenario A: Artificial pancreas malfunction

An automated insulin-delivery system provides an excessive insulin dose, causing severe hypoglycaemia.

Legal questions: Was the device defective? Were its alarms adequate? Was the system correctly configured? Did the clinician or manufacturer fail to meet an applicable duty?

Possible remedies: Medical-negligence damages, product-liability remedies, regulatory reporting and corrective action, depending on the evidence.

Scenario B: Hormonal implant without valid consent

A clinician inserts a long-acting hormonal implant without adequately explaining material risks or obtaining valid consent.

Legal questions: Was consent voluntary and informed? Was the intervention authorised? Was the patient competent to consent?

Relevant authority: Samira Kohli v. Dr. Prabha Manchanda.

Scenario C: Unauthorised disclosure of hormone data

A private platform discloses endocrine monitoring records to an employer, which uses them to make employment decisions.

Legal questions: Was the data processing lawful? Were applicable privacy obligations breached? Did the employment decision amount to unlawful discrimination?

Relevant authority: K.S. Puttaswamy v. Union of India, alongside applicable data-protection and employment law.

Scenario D: Experimental hormone-regulating implant

A research organisation offers an experimental implant that regulates hormone production without complying with applicable clinical-trial or product authorisation requirements.

Legal questions: Was regulatory permission required? Were participants adequately informed? Were research ethics and safety requirements followed?

Possible consequences: Regulatory action, civil liability or other legal consequences where the relevant statutory elements are established.

7. Constitutional and ethical limits

The proposed doctrine must distinguish legitimate medical treatment from coercive physiological control.

Bodily integrity: Hormonal interventions can affect fertility, metabolism, mood, growth and sexual development. Their importance strengthens the case for meaningful consent and proportionate safeguards.

Reproductive autonomy: Decisions concerning fertility and reproductive health may engage privacy, dignity and personal liberty. Medical necessity and the rights of other affected persons must be assessed under applicable law.

Children and persons lacking capacity: Decisions must follow the relevant consent, guardianship, best-interests and medical-care framework. A guardian's involvement does not eliminate all legal limits on invasive or experimental treatment.

Equality: Endocrine measurements should not be treated as definitive proof of a person's competence, character, productivity or suitability for employment. Any adverse decision must be assessed under applicable equality and discrimination law.

Scientific uncertainty: Hormone-regulating technologies can have long-term effects that are not fully understood at the time of intervention. Proportionate monitoring and transparent communication of material uncertainty are therefore important.

8. Proposed regulatory model

A practical Artificial Endocrine Governance Framework could contain the following safeguards:

Pre-market assessment: Appropriate evidence of safety, quality and performance for the relevant medicine, device or combination product.

Informed consent: Clear explanation of intended effects, material risks, alternatives, reversibility and monitoring requirements.

Traceability: Records of product batches, device settings, software versions and clinically significant changes.

Post-market surveillance: Reporting of adverse events, investigation of failures and corrective action.

Algorithmic accountability: Appropriate validation, change control, human oversight and audit trails for automated endocrine management.

Data governance: Purpose limitation, security, access controls and compliance with applicable data-protection law.

Effective remedies: Accessible complaint procedures, compensation where legally justified and independent review of disputed decisions.

These are proposed governance measures. They should not be mistaken for a claim that every measure is already expressly mandated by a single Indian statute.

9. Conclusion

The Artificial Endocrine Doctrine is best understood as a proposed legal framework for ensuring that technologies influencing hormonal function remain safe, accountable and respectful of human dignity.

Its principal foundations in Indian law are:

Samira Kohli v. Dr. Prabha Manchanda — informed consent and bodily autonomy.

K.S. Puttaswamy v. Union of India — privacy, dignity and decisional autonomy.

Indian Kanoon

+1

Common Cause v. Union of India — dignity and medical decision-making.

Indian Medical Association v. V.P. Shantha — consumer remedies for qualifying medical services.

Indian Kanoon

The central proposition is that artificial regulation of the endocrine system must not displace the patient's legal rights or eliminate accountability for preventable harm. Existing medical, constitutional, consumer and data-protection law can address many of these issues, while genuinely novel technologies may require more specific legislation and regulatory guidance.

Research note: The cases discussed above establish general legal principles, not a separately recognised doctrine bearing the name “Artificial Endocrine Doctrine.” For litigation or academic publication, statutory provisions and subsequent judgments should be checked against the precise technology and facts in question.